2025-03-31 18:34:22
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Bliss GVS Pharma Ltd Q3 FY24 consolidated PAT slips to Rs. 27.61 crores
Posted On : 2024-01-24 09:04:20( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended December 31, 2023.
Financial Results (Q3 FY2024) - QoQ Comparison
The company has reported total income of Rs. 206.1412 crores during the period ended December 31, 2023 as compared to Rs. 224.4789 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs. 27.6102 crores for the period ended December 31, 2023 as against net profit / (loss) of Rs. 42.3065 crores for the period ended September 30, 2023.
The company has reported EPS of Rs. 2.60 for the period ended December 31, 2023 as compared to Rs. 3.98 for the period ended September 30, 2023.
| Financials | Q3 FY2024 | Q2 FY2024 | % Change |
| Total Income | ₹ 206.1412 crs | ₹224.4789 crs |  -8.17% |
| Net Profit | ₹27.6102 crs | ₹42.3065 crs | -34.74% |
| EPS | ₹2.60 | ₹3.98 | -34.67% |
Financial Results (Q3 FY2024) - YoY Comparison
The company has reported total income of Rs. 206.1412 crores during the period ended December 31, 2023 as compared to Rs.211.3635 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs.27.6102 crores for the period ended December 31, 2023 as against net profit / (loss) of Rs.27.9419 crores for the period ended December 31, 2022.
The company has reported EPS of Rs.2.60 for the period ended December 31, 2023 as compared to Rs.2.64 for the period ended December 31, 2022.
| Financials | Q3 FY2024 | Q3 FY2023 | % Change |
| Total Income | ₹ 206.1412 crs | ₹211.3635 crs | -2.47% |
| Net Profit | ₹27.6102 crs | ₹27.9419 crs | -1.19% |
| EPS | ₹2.60 | ₹2.64 | -1.52% |
Financial Results (9 Months Ended FY2024) - YoY Comparison
The company has reported total income of Rs.595.2545 crores during the 9 Months period ended December 31, 2023 as compared to Rs.581.6170 crores during the 9 Months period ended December 31, 2022.
The company has posted net profit / (loss) of Rs.84.6018 crores for the 9 Months period ended December 31, 2023 as against net profit / (loss) of Rs.67.5150 crores for the 9 Months period ended December 31, 2022.
The company has reported EPS of Rs.7.97 for the 9 Months period ended December 31, 2023 as compared to Rs.6.39 for the 9 Months period ended December 31, 2022.
| Financials | 9 Months Ended FY2024 | 9 Months Ended FY2023 | % Change |
| Total Income | ₹595.2545 crs | ₹581.6170 crs |  2.34% |
| Net Profit | ₹84.6018 crs | ₹67.5150 crs | 25.31% |
| EPS | ₹7.97 | ₹6.39 | 24.73% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 122.55 as compared to the previous close of Rs. 126.10. The total number of shares traded during the day was 59819 in over 1229 trades.
The stock hit an intraday high of Rs. 129.85 and intraday low of 121.55. The net turnover during the day was Rs. 7522396.00.
